GiorgiGugenishvili

Associate

Paris + 33.1.56.59.46.07

Connect:

Share

Giorgi Gugenishvili assists French and international clients in contentious and noncontentious matters related to intellectual property (trademarks, copyright, domain names, patents), data protection, and information technology.

Prior to joining Jones Day in 2023, Giorgi completed internships at several international law firms, a leading French communications company, and a prominent French start-up in the gaming industry. While at university, he also worked as a legal research assistant on a European Research Council-funded project.

Experience

  • Chalfen Ventures leads $18 million Series A financing of Polar AnalyticsJones Day advised Chalfen Ventures as lead investor in the $18 million Series A financing of Polar Analytics, a French startup that develops software empowering consumer brands.
  • Amolyt Pharma acquired by AstraZenecaJones Day advised Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • Partech Partners leads €37 million Series B financing of CintooJones Day represented Partech Partners as lead investor in the €37 million Series B financing of Cintoo, the leading provider of cloud-based Reality Data management and collaboration solutions.
    • View All

    November 2023 Commentary

    Patent Marking and e-Marking in Europe: Maximizing Benefits and Avoiding Pitfalls

    Additional Publications

    • 2024
      Intellectual Property Rights in France Overview, Practical Law Country Q&A
    • 2024
      Intellectual Property Transactions in France Overview, Practical Law Country Q&A

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.